J. Grob

发表

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

A. Hauschild, C. Blank, W. Miller, 2012, The Lancet.

The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma).

J. Grob, M. Richard, C. Gaudy-Marqueste, 2011, Journal of the American Academy of Dermatology.

Delays in diagnosis and melanoma prognosis (I): The role of patients

J. Grob, B. Dréno, M. Richard, 2000, International journal of cancer.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

J. Larkin, A. Ribas, C. Blank, 2015, The New England journal of medicine.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2017, The New England journal of medicine.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Melanoma and tumor thickness: challenges of early diagnosis.

J. Grob, B. Dréno, M. Richard, 1999, Archives of dermatology.

First prospective study of the recognition process of melanoma in dermatological practice.

J. Grob, M. Richard, J. Gachon, 2005, Archives of dermatology.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

James R. Anderson, R. Dummer, J. Larkin, 2019, The Lancet. Oncology.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

D. Schadendorf, P. Ascierto, R. Dummer, 2019, The New England journal of medicine.

The role of BRAF V600 mutation in melanoma

Alessandro Testori, Paolo A Ascierto, Giuseppe Palmieri, 2012, Journal of Translational Medicine.

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions

C Beauvillain, J. Lemonnier, J. Grob, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Axel Hoos, Alessandro Testori, Axel Hauschild, 2011, The New England journal of medicine.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.

O. Faye, J. Roujeau, J. Grob, 2008, Journal of the American Academy of Dermatology.

Naevi in allogeneic bone marrow transplantation recipients: the effect of graft‐versus‐host disease on naevi

D. Blaise, J. Grob, M. Richard, 2002, The British journal of dermatology.

Multiple senile lentigos of the face, a skin ageing pattern resulting from a life excess of intermittent sun exposure in dark‐skinned caucasians: a case–control study

J. Grob, M. Richard, J. Gouvernet, 2006, The British journal of dermatology.

Consensus Clustering From Experts' Partitions for Patients' nevi: Model the Ugly Duckling

Sébastien Paris, Gloria Menegaz, Julien Lefèvre, 2012, DMIN 2012.

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy.

J. Régis, J. Grob, M. Richard, 2006, International journal of radiation oncology, biology, physics.

Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients

E. Tartour, W. Fridman, N. Bercovici, 2008, Journal of immunotherapy.

An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).

A. Hauschild, C. Blank, W. Miller, 2013 .

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma

B. Asselain, M. Dutreix, J. Grob, 2016, British Journal of Cancer.

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

B. Neyns, J. Grob, C. Robert, 2017, ESMO Open.

Study of sunbathing habits in children and adolescents: application to the prevention of melanoma.

H. Zarour, J. Grob, J. Bonerandi, 1993, Dermatology.

Ugly Duckling Sign as a Major Factor of Efficiency in Melanoma Detection

Raoul Triller, Giovanni Pellacani, Josep Malvehy, 2017, JAMA dermatology.

Diabetes and Blood Glucose Disorders Under Anti-PD1

J. Grob, S. Mallet, M. Richard, 2018, Journal of immunotherapy.

Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

P. Ascierto, R. Dummer, J. Wolchok, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life

P. Auquier, J. Ortonne, J. Grob, 2009, Allergy.

Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma

J. Grob, M. Richard, J. Bonerandi, 2006, Journal of cutaneous medicine and surgery.

Component‐resolved diagnosis with commercially available D. pteronyssinus Der p 1, Der p 2 and Der p 10: relevant markers for house dust mite allergy

P. Berbis, J. Grob, P. Bongrand, 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

A. Hauschild, P. Ascierto, R. Dummer, 2016, The New England journal of medicine.

Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

D. Schadendorf, C. Horak, R. Dummer, 2017 .

Accidents thrombotiques favorisés par le thalidomide : deux observations

J. Grob, M. Richard, J. Gachon, 2002 .

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

P. Ascierto, J. Larkin, A. Ribas, 2017, Journal of Translational Medicine.

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

I. Zalaudek, A. Hauschild, J. Malvehy, 2019, European journal of cancer.

Basal Cell Carcinomas and Actinic Keratoses Seen in Dermatological Practice in France: A Cross-Sectional Survey

A. Sasco, J. Grob, A. Dupuy, 2008, Dermatology.

Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries.

A. Hauschild, P. Hersey, L. Bastholt, 2015, American journal of therapeutics.

Urticaria and quality of life

J. Grob, C. Gaudy-Marqueste, 2006, Clinical reviews in allergy & immunology.

[Campaign of early detection of melanoma in the Provence-Alpes-Côte-d'Azur area 1989. Lessons of an experience].

J. Grob, J. Bonerandi, J. Gouvernet, 1992, Annales de dermatologie et de venereologie.

Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.

P. Berbis, J. Grob, N. Jourde-Chiche, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior.

A. Dunant, J. Grob, A. Dupuy, 2005, Archives of dermatology.

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

D. Schadendorf, P. Ascierto, E. Lipson, 2022, The New England journal of medicine.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

A. Eggermont, A. Testori, J. Grob, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma

D. Olive, J. Grob, J. Monnier, 2021, Cancers.

Expression of FGF1 and FGFR1 in human melanoma tissues

D. Birnbaum, L. Xerri, J. Grob, 1996, Melanoma research.

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

D. Schadendorf, V. Sondak, P. Ascierto, 2022, The Lancet.

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

J. Wolchok, A. Ribas, F. Hodi, 2021, European journal of cancer.

Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.

D. Schadendorf, L. Garraway, S. Jaeger, 2016 .

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.

J. Larkin, A. Ribas, C. Blank, 2016 .

3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)

J. Wolchok, J. Larkin, F. Hodi, 2015 .

Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)

P. Ascierto, H. Schmidt, L. Bastholt, 2016 .

Not all melanomas are created equal: a review and call for more research into nodular melanoma

A. Lallas, R. Scolyer, C. Garbe, 2021, The British journal of dermatology.

Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma

J. Grob, J. Bonerandi, J. Gouvernet, 1990, Cancer.

Role of sun exposure on nevus. First study in age-sex phenotype-controlled populations.

H. Zarour, J. Grob, M. Richard, 1993, Archives of dermatology.

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

D. Schadendorf, P. Ascierto, M. Smylie, 2020, Journal for immunotherapy of cancer.

Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.

J. Régis, J. Grob, R. Carron, 2020, European journal of cancer.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

P. Ascierto, J. Larkin, M. Atkins, 2017, The New England journal of medicine.

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

J. Grob, S. Mallet, M. Richard, 2015, Diabetes Care.

Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey

J. Roujeau, J. Grob, J. Revuz, 2008, Dermatology.

Insulin-Induced Lipoatrophy in Type I Diabetes: A possible tumor necrosis factor-α-mediated dedifferentiation of adipocytes

L. Xerri, J. Grob, P. Bongrand, 1996, Diabetes Care.

Cutaneous manifestations associated with the presence of the lupus anticoagulant. A report of two cases and a review of the literature.

J. Grob, J. Bonerandi, 1986, Journal of the American Academy of Dermatology.

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

LBR mutation and nuclear envelope defects in a patient affected with Reynolds syndrome

J. Grob, N. Lévy, C. Gaudy-Marqueste, 2010, Journal of Medical Genetics.

LMNA, ZMPSTE24, and LBR are not mutated in scleroderma.

J. Grob, N. Lévy, C. Gaudy-Marqueste, 2009, Genetic testing and molecular biomarkers.

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.

J. Grob, A. Cohen, F. Barlesi, 2017, Circulation.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

A. Hauschild, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia.

J. Grob, G. Magalon, P. Disdier, 1991, Dermatologica.

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

D. Schadendorf, P. Ascierto, R. Dummer, 2018, The Lancet. Oncology.

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.

J. Régis, J. Grob, S. Mallet, 2017, European journal of cancer.

Physiopathogenic Investigations in a Case of Familial Stiff-Skin Syndrome

J. Grob, M. Richard, F. Faure, 1998, Dermatology.

A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.

J. Grob, M. Richard, J. Franques, 2013, Journal of immunotherapy.

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.

J. Grob, F. Albarel, I. Morange, 2015, European journal of endocrinology.

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

J. Wolchok, S. Aamdal, A. Testori, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining and recognising locally advanced basal cell carcinoma

J. Grob, B. Dréno, N. Basset-Seguin, 2015, European Journal of Dermatology.

Fibroblast growth factor gene expression in AIDS-Kaposi's sarcoma detected by in situ hybridization.

D. Birnbaum, L. Xerri, J. Grob, 1991, The American journal of pathology.

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

J. Grob, C. Lebbé, O. Dereure, 2022, Annals of the Rheumatic Diseases.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)

G. Madonna, P. Ascierto, L. Zitvogel, 2022, Journal of Translational Medicine.

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

I. Zalaudek, J. Malvehy, R. Dummer, 2019, European journal of cancer.

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.

D. Olive, M. Mohty, J. Grob, 2010, Immunobiology.

Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study

J. Grob, C. Gaudy-Marqueste, N. Macagno, 2021, Melanoma research.

P. Ascierto, R. Dummer, J. Wolchok, 2017, The Lancet. Oncology.

Ara h 2 and Ara h 6 sensitization predicts peanut allergy in Mediterranean pediatric patients

J. Sarles, J. Grob, P. Bongrand, 2014, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double‐blind, multicentre, placebo‐controlled study

P. Auquier, J. Ortonne, J. Grob, 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

P. Ascierto, J. Larkin, A. Arance, 2020, The Lancet. Oncology.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

P. Ascierto, R. Dummer, J. Wolchok, 2019, European journal of cancer.

Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

P. Ascierto, R. Dummer, J. Wolchok, 2019, Journal of Clinical Oncology.

Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib

D. Schadendorf, A. Ribas, D. Polsky, 2021 .

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019

P. Ascierto, H. Zarour, A. Testori, 2020, Journal of Translational Medicine.

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

James R. Anderson, J. Larkin, A. Ribas, 2018 .

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

D. Schadendorf, R. Dummer, J. Wolchok, 2022, Journal of Clinical Oncology.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.

J. Grob, C. Lebbé, O. Dereure, 2022, European journal of cancer.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

A. Hauschild, P. Ascierto, R. Dummer, 2015, The Lancet. Oncology.

Analysis of T-cell receptor-γ gene rearrangements using heteroduplex analysis by high-resolution microcapillary electrophoresis.

C. Formisano-Tréziny, J. Gabert, J. Grob, 2012, Leukemia research.

Antiinflammatory properties of cetirizine in a human contact dermatitis model. Clinical evaluation of patch tests is not hampered by antihistamines.

J. Grob, M. Richard, J. Bonerandi, 1998, Acta Dermato-Venereologica.

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

D. Schadendorf, S. Puig, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.

D. Schadendorf, P. Dziewulski, A. Eggermont, 2020, European journal of cancer.

Multiple primary melanoma is not a distinct biological entity.

J. Grob, 1999, Archives of dermatology.

Cutaneous lymphomas of phenotypically undetermined lineage: contribution of genotypic analysis.

L. Xerri, J. Grob, J. Hassoun, 1991, Journal of the American Academy of Dermatology.

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

P. Ascierto, A. Arance, P. Queirolo, 2022, European journal of cancer.

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

J. Utikal, C. Berking, A. Hauschild, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2019, European journal of cancer.

Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials

A. Hauschild, D. Schadendorf, P. Ascierto, 2021 .

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

Lupus Erythematosus and Its Subsets

J. Grob, J. Bonerandi, R. Watson, 1988 .

[Systemic treatment of melanoma brain metastases].

J. Grob, T. Jouary, C. Lebbé, 2015, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Dermatomyositis-like syndrome induced by nonsteroidal anti-inflammatory agents.

J. Grob, J. Bonerandi, A. Collet, 1989, Dermatologica.

Stiff-skin syndrome Congenital fascial dystrophy Cytokines

J. Grob, F. Faure, J. Bonerandi, 1998 .

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

J. Larkin, A. Ribas, C. Blank, 2020 .

1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

Charles H. Yoon, D. Schadendorf, P. Ascierto, 2022, The Lancet. Oncology.

NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival.

L. Xerri, J. Grob, J. Bonerandi, 1994, British Journal of Cancer.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.

S. Spector, C. Bindslev‐Jensen, J. Grob, 2015, The Journal of investigative dermatology.

Erratum: Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study (Journal of Investigative Dermatology (2015) 135 (67-75)) DOI: 10.1038/jid.2014.306)

S. Spector, C. Bindslev‐Jensen, J. Grob, 2015 .

Sweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia.

J. Grob, M. Richard, Y. Berland, 1996, Journal of the American Academy of Dermatology.

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

P. Ascierto, A. Arance, M. Mandalà, 2019, Annals of Oncology.

Extra-anogenital HPV16-related bowenoid papulosis.

H. Zarour, J. Grob, J. Bonerandi, 1991, Genitourinary medicine.

Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial

S. D'Angelo, M. Burgess, J. Grob, 2020, The Patient - Patient-Centered Outcomes Research.

Pancreatitis associated protein I (PAP-I) alters adhesion and motility of human melanocytes and melanoma cells.

J. Grob, J. Dagorn, J. Iovanna, 2001, The Journal of investigative dermatology.

Development of a treatment algorithm for actinic keratoses: a European Consensus.

H. Pehamberger, H. Kerl, J. Grob, 2008, European journal of dermatology : EJD.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild, D. Schadendorf, P. Ascierto, 2017, European journal of cancer.

Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.

J. Grob, C. Lebbé, O. Dereure, 2022, Journal of the American Academy of Dermatology.

Disseminated pustular dermatosis in polycythemia vera. Relationship with neutrophilic dermatosis of myeloproliferative disorders: study of neutrophil function.

J. Grob, J. Bonerandi, A. Prax, 1988, Journal of the American Academy of Dermatology.

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

P. Ascierto, J. Larkin, A. Arance, 2017 .

Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life

P. Auquier, J. Grob, J. Revuz, 2005, The British journal of dermatology.

Randomized clinical trials for psoriasis 1977-2000: the EDEN survey.

H. Williams, L. Naldi, P. Elsner, 2003, The Journal of investigative dermatology.

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

A. Hauschild, A. Arance, C. Garbe, 2014, Cancer.

[Impetigo herpetiformis, a rare manifestation of severe hypocalcemia].

J. Grob, B. Vialettes, R. Valéro, 2002, Annales d'Endocrinologie.

Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.

J. Malvehy, H. Pehamberger, K. Peris, 2015, European journal of cancer.

Skin protection by sunscreens is improved by explicit labeling and providing free sunscreen.

J. Grob, J. Gouvernet, Caroline Gaudy, 2007, The Journal of investigative dermatology.

Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France.

H. Zarour, J. Grob, M. Richard, 1995, Dermatology.

Melanoma prevention: evaluation of a health education campaign for primary schools.

J. Grob, J. Guillaume, S. Bastuji‐Garin, 1999, Archives of dermatology.

Response to “Changing the Labeling of Sunscreen, Will We Transform Sun Avoiders into Sunscreen Users?”

J. Grob, C. Gaudy-Marqueste, 2008 .

Contact urticaria from rifamycin

J. Grob, J. Bonerandi, G. Pommier, 1987, Contact dermatitis.

Epidemiology, causes, and prevention of skin diseases

J. J. Grob, J. Grob, 1997 .

Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo.

J. Mege, J. Grob, P. Bongrand, 1991, Journal of the American Academy of Dermatology.

Risk factors for erysipelas of the leg (cellulitis): case-control study

L. Vaillant, J. Roujeau, J. Grob, 1999, BMJ.

Immunoblot Assay is Still Useful For the Serological Diagnosis of Autoimmune Bullous Dermatosis

P. Berbis, J. Grob, M. Richard, 2012 .

Ofuji papuloerythroderma. Report of a case with T cell skin lymphoma and discussion of the nature of this disease.

J. Grob, J. Bonerandi, L. Prin, 1989, Journal of the American Academy of Dermatology.

French people and skin diseases: results of a survey using a representative sample.

J. Roujeau, J. Grob, P. Wolkenstein, 2003, Archives of dermatology.

Quality of life in alopecia areata: a study of 60 cases.

P. Auquier, J. Grob, M. Richard, 2010, The Journal of investigative dermatology.

Keratitis, ichthyosis, and deafness (KID) syndrome. Vertical transmission and death from multiple squamous cell carcinomas.

J. Grob, J. Bonerandi, A. Breton, 1987 .

Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.

A. Hauschild, D. Schadendorf, S. Puig, 2017, The Lancet. Oncology.

[Dermatitis ulcerosa or superficial granulomatous pyoderma. Functional abnormalities of the neutrophils and transient efficacy of clofazimine].

J. Grob, J. Bonerandi, J. Mege, 1989, Annales de dermatologie et de venereologie.

Skin necrosis after injection of aminosides. Arthus reaction, local toxicity, thrombotic process or pathergy?

J. Grob, J. Bonerandi, L. Andrac, 1990, Dermatologica.

[Skin manifestations associated with myelodysplastic syndromes].

J. Grob, M. Richard, F. Carsuzaa, 2001, La Revue de medecine interne.

Epidemiology of skin diseases in Europe.

L. Naldi, P. Elsner, J. Bouwes Bavinck, 2006, European journal of dermatology : EJD.

Development and Validation of a Quality of Life Measurement for Chronic Skin Disorders in French: VQ-Dermato

C. Lançon, P. Auquier, J. Grob, 1999, Dermatology.

Palmoplantar orthokeratotic filiform hyperkeratosis in a patient with associated Darier's disease. Classification of filiform hyperkeratosis.

H. Zarour, J. Grob, J. Bonerandi, 1992, Dermatology.

Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.

Jean-Jacques Grob, Sandeep Varma, J. Grob, 2004, Archives of dermatology.

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.

I. Zalaudek, J. Becker, J. Malvehy, 2015, European journal of cancer.

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

J. Schachter, J. Grob, R. Gonzalez, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline.

J. Becker, J. Malvehy, H. Pehamberger, 2015, European journal of cancer.

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

J. Grob, C. Robert, C. Lebbé, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

A. Ribas, C. Blank, A. Arance, 2017, The Lancet.

J. Schachter, J. Grob, N. Basset-Seguin, 2021, Dermatology and Therapy.

Large keratoacanthomas treated with intralesional interferon alfa-2a.

H. Zarour, J. Grob, M. Richard, 1993, Journal of the American Academy of Dermatology.

[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].

J. Grob, M. Richard, C. Gaudy-Marqueste, 2016, Annales de dermatologie et de venereologie.

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2010, European journal of cancer.

[Treatment of keratoacanthoma with intralesional methotrexate injections].

J. Grob, M. Richard, J. Gachon, 2000, Annales de dermatologie et de venereologie.

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

C. Garbe, E. Espinosa, A. Schueler, 2020, Cancers.

Tyrosinase gene expression in human tissues.

L. Xerri, J. Grob, J. Bonerandi, 1993, Pigment cell research.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

J. Larkin, A. Ribas, C. Blank, 2019, The Lancet. Oncology.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

D. Schadendorf, R. Dummer, J. Wolchok, 2018, The Lancet. Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

C. Chastang, J. Grob, B. Dréno, 1998, The Lancet.

[Kinetic values of lymphoscintigraphy of sentinel ganglion in cutaneous cervicofacial melanomas].

J. Grob, S. Duflo, M. Zanaret, 2010, Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale.

Identification by cDNA microarray technology of genes modulated by artificial ultraviolet radiation in normal human melanocytes: relation to melanocarcinogenesis.

J. Grob, P. Verrando, C. Valéry, 2001, The Journal of investigative dermatology.

Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma.

L. Xerri, H. Zarour, J. Grob, 1995, Archives of dermatology.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Smylie, 2017, The Lancet. Oncology.

Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

A. Eggermont, J. Grob, V. Chiarion-Sileni, 2015, The Lancet. Oncology.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

P. Ascierto, R. Dummer, J. Wolchok, 2015, The Lancet. Oncology.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

D. Schadendorf, G. Linette, J. Wolchok, 2010, The Lancet. Oncology.

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma

A. Hauschild, R. Dummer, A. Eggermont, 2012, Expert opinion on biological therapy.

White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma.

C. Chastang, J. Grob, B. Dréno, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Photodynamic Therapy Using Topical Methyl Aminolevulinate vs Surgery for Nodular Basal Cell Carcinoma

J. Grob, P. Wolf, S. Varma, 2013 .

Photodynamic Therapy Using Topical Methyl Aminolevulinate vs Surgeryfor Nodular Basal Cell Carcinoma: Results of a Multicenter Randomized Prospective Trial

J. Grob, P. Wolf, S. Varma, 2004 .

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.

D. Schadendorf, K. Flaherty, A. Ribas, 2021, The Lancet. Oncology.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.

A. Lallas, I. Zalaudek, A. Hauschild, 2020, European journal of cancer.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

D. Schadendorf, S. Puig, P. Ascierto, 2020, JAMA oncology.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

Giovanni Pellacani, Josep Malvehy, Axel Hauschild, 2019, European journal of cancer.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

D. Schadendorf, S. Puig, P. Ascierto, 2018, The New England journal of medicine.

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

A. Hauschild, D. Schadendorf, S. Ugurel, 2016, European journal of cancer.

Diagnosis and treatment of melanoma . European consensus-based interdisciplinary guideline e Update 2016

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2016 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Molecular characterization of fast-growing melanomas.

Rajiv Kumar, P. Mundra, R. Marais, 2021, Journal of the American Academy of Dermatology.

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

V. Sondak, P. Ascierto, M. Atkins, 2021, Journal of translational medicine.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

A. Hauschild, K. Flaherty, J. Larkin, 2014 .

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma

S. Granjeaud, D. Olive, E. Tartour, 2019, Oncoimmunology.

[Treatment of Hailey-Hailey disease with carbon dioxide laser vaporization].

J. Grob, M. Richard, F. Fourquet, 2005, Annales de dermatologie et de venereologie.

The role of BRAF V600 mutation in melanoma

F. Marincola, P. Ascierto, J. Kirkwood, 2012, Journal of Translational Medicine.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2012, European journal of cancer.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Matthew Wongchenko, Jeffrey E Gershenwald, Lauren E Haydu, 2018, The Lancet. Oncology.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

D. Schadendorf, R. Dummer, J. Wolchok, 2017, JAMA oncology.

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

D. Schadendorf, R. Dummer, J. Wolchok, 2021 .

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Ying Zhang, Jean-Jacques Grob, Keith T Flaherty, 2017, The Lancet. Oncology.

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

D. Schadendorf, P. Ascierto, E. Lipson, 2021 .

Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low–normal serum lactate dehydrogenase: ‘The AGENDA trial’

C. Garbe, J. Grob, C. Lebbé, 2014, Melanoma research.

Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.

J. Grob, T. Jouary, M. Richard, 2014, Acta dermato-venereologica.

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.

A. Hauschild, S. Ugurel, W. Guo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.

A. Hauschild, P. Ascierto, H. Gogas, 2013, Critical reviews in oncology/hematology.

Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report.

J. Grob, B. Dréno, M. Avril, 2007, European journal of dermatology : EJD.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.

A. Hauschild, J. Malvehy, H. Pehamberger, 2012, European journal of cancer.

Quality of life and skin diseases: be careful with counterfeit . . .

J. Grob, 2009, Archives of dermatology.

Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders?

J. Grob, 2007, The Journal of investigative dermatology.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

A. Hauschild, D. Schadendorf, S. Ugurel, 2017, European journal of cancer.

Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials.

D. Schadendorf, K. Flaherty, J. Grob, 2015, The Lancet. Oncology.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.

J. Régis, J. Grob, M. Richard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

A. Hauschild, W. Miller, P. Rutkowski, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.

P. Petrow, M. Boubaya, J. Grob, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.

J. Grob, C. Lebbé, S. Prey, 2020, JAMA dermatology.

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.

Charles H. Yoon, A. Hauschild, James R. Anderson, 2019, Future oncology.

Le syndrome de Sneddon

J. Grob, M. Richard, J. Durand, 1994 .

Human Polyomavirus-6 Infecting Lymph Nodes of a Patient With an Angiolymphoid Hyperplasia With Eosinophilia or Kimura Disease.

C. Desnues, D. Raoult, H. Lepidi, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

J. Grob, C. Lebbé, T. Gambichler, 2018, JAMA oncology.

[Cutaneous signs of Noonan's syndrome. Apropos of a case with ulerythema ophyogenes, disseminated pilar and sudoral keratosis and progressive alopecia].

J. Grob, J. Bonerandi, L. Andrac, 1988, Annales de dermatologie et de venereologie.

[Isolated late-onset plexiform neurofibroma in the absence of neurofibromatosis].

J. Grob, S. Mallet, M. Richard, 2010, Annales de dermatologie et de venereologie.

Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis

J. Grob, L. Ouafik, N. Beaufils, 2022, Cancers.

Pepper Mild Mottle Virus, a Plant Virus Associated with Specific Immune Responses, Fever, Abdominal Pains, and Pruritus in Humans

C. Desnues, D. Raoult, P. Berbis, 2010, PloS one.

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

D. Schadendorf, K. Flaherty, A. Ribas, 2016, The Lancet. Oncology.

Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2016 .

[Congenital universal hypertrichosis].

J. Grob, M. Richard, C. Gaudy-Marqueste, 2009, Annales de dermatologie et de venereologie.

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Parantu K. Shah, J. Grob, C. Lebbé, 2021, Journal for ImmunoTherapy of Cancer.

Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.

S. Chevret, J. Grob, T. Jouary, 2022, European journal of cancer.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

A. Hauschild, P. Ascierto, R. Dummer, 2018, European Journal of Dermatology.

Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.

P. Petrow, M. Boubaya, J. Grob, 2019, Journal of Clinical Oncology.

Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study.

J. Grob, C. Robert, C. Lebbé, 2017 .

Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.

A. Hauschild, P. Ascierto, R. Dummer, 2015 .

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening.

J. Grob, J. Bonerandi, J J Grob, 1998, Archives of dermatology.

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial.

A. Hauschild, H. Pehamberger, M. Landthaler, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone.

C. Garbe, J. Grob, C. Lebbé, 2010 .

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

C. Chastang, J. Grob, B. Dréno, 1998, Lancet.

Vismodegib efficacy in unresectable trichoblastic carcinoma: a multicenter study of 16 cases.

J. Grob, T. Jouary, H. Maillard, 2021, Journal of American Academy of Dermatology.

Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire

J. Grob, M. Richard, J. Mancini, 2021, Quality of Life Research.

[Congenital hypotrichosis and milia with spontaneous regression during adolescence or Oley syndrome: a variant of Bazex-Dupré-Christol syndrome].

J. Grob, M. Richard, V. Andreani, 2000, Annales de dermatologie et de venereologie.

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.

A. Hauschild, D. Schadendorf, J. Becker, 2020, European journal of cancer.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Slow Dynamics of Lymphoscintigraphic Mapping Is Associated to the Negativity of the Sentinel Node in Melanoma Patients

J. Grob, M. Richard, O. Mundler, 2008, Annals of Surgical Oncology.

Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?

J. Grob, C. Lebbé, B. Dréno, 2021, Annales de dermatologie et de venereologie.

[Cutaneous metastasis of pleural mesothelioma: two cases].

J. Grob, M. Richard, C. Gaudy-Marqueste, 2003, Annales de dermatologie et de venereologie.

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.

A. Hauschild, H. Pehamberger, M. Landthaler, 2013, European journal of cancer.

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

D. Schadendorf, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

A. Hauschild, P. Ascierto, R. Dummer, 2016 .

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France

S. Michiels, J. Grob, C. Lebbé, 2022, Current oncology.

Quality‐of‐life assessment in French patients with metastatic melanoma in real life

S. Michiels, J. Grob, C. Lebbé, 2020, Cancer.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dirk Schadendorf, Axel Hauschild, Antoni Ribas, 2019, European journal of cancer.

Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives

J. Grob, N. Malissen, 2018, Drugs.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

D. Schadendorf, P. Ascierto, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

D. Schadendorf, A. Abernethy, R. Dummer, 2017, European journal of cancer.

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

D. Schadendorf, M. Ross, P. Ascierto, 2022, European journal of cancer.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Hauschild, S. Puig, J. Goeman, 2018, The Lancet. Oncology.

Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review

J. Grob, T. Jouary, J. Lear, 2017, European Journal of Dermatology.

Treatment of Recurrent Melanoma Following Adjuvant Therapy

J. Grob, N. Malissen, 2023, American Journal of Clinical Dermatology.

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

D. Schadendorf, P. Ascierto, R. Dummer, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cognitive training with photographs as a new concept in an education campaign for self‐detection of melanoma: a pilot study in the community

J. Grob, M. Richard, C. Gaudy-Marqueste, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: A randomized study

Joanny Gouvernet, Caroline Gaudy, Jean-Jacques Grob, 2006, International journal of cancer.

Treatment Algorithms in Stage IV Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2015, American journal of therapeutics.

3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study

A. Hauschild, P. Ascierto, R. Dummer, 2015 .

Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision

Niklas Hartung, Florence Hubert, Jean-Jacques Grob, 2017, PloS one.

The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force

A. Enk, M. Arenbergerova, A. Lallas, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Adhesive and migratory behaviors of nevus cells differ from those of epidermal melanocytes and are not linked to the histological type of nevus.

J. Grob, M. Richard, P. Bongrand, 1996, The Journal of investigative dermatology.

Role of tumor necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosis

J. Mege, J. Grob, P. Bongrand, 1991 .

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2008, Clinical Cancer Research.

[Epidemiology of mycosis fungoides].

J. Grob, 2005, Annales de dermatologie et de venereologie.

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2022, European journal of cancer.

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.

A. Hauschild, C. Blank, P. Rutkowski, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

P. Ascierto, M. Del Vecchio, M. Mandalà, 2021, Journal for ImmunoTherapy of Cancer.

Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma

J. Grob, M. Richard, J. Bonerandi, 1998, Melanoma research.

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).

P. Ascierto, R. Dummer, J. Larkin, 2018 .

Sinonasal mucosal melanomas: The prognostic value of tumor classifications

J. Grob, M. Richard, J. Michel, 2014, Head & neck.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

[Granulomas induced by injections of leuprorelin acetate (Enantone®)].

J. Grob, M. Richard, C. Gaudy-Marqueste, 2011, Annales de dermatologie et de venereologie.

[Which diagnostic tools in melanoma and why?].

J. Grob, 2008, Annales de dermatologie et de venereologie.

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

D. Schadendorf, R. Dummer, J. Wolchok, 2019, Annals of Oncology.

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, Journal of Clinical Oncology.

Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma.

J. Grob, M. Richard, A. Loundou, 2014, European journal of cancer.

The relation between seborrheic keratoses and malignant solid tumours. A case-control study.

J. Sarles, M. Gamerre, J. Grob, 1991, Acta dermato-venereologica.

[Role of sun exposure on benign melanocytic nevi. A first study in populations controlled for age, sex and phenotype].

J. Grob, M. Richard, J. Bonerandi, 1994, Annales de dermatologie et de venereologie.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

[Epidemiology and prevention of melanoma].

J. Grob, M. Richard, 2004, La Revue du praticien.

[Trigeminal neurotrophic ulcer and vascular disorders of the brain stem. A clinico-electrophysiological study].

J. Grob, J. Pouget, J. Bonerandi, 1992, Revue neurologique.

[Physiopathology of nevi and nevocytes].

J. Grob, M. Jreissati, 1998, Annales de dermatologie et de venereologie.

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.

F. Fagnani, J. Grob, B. Dréno, 2001, European journal of cancer.

[Bullous cutaneous localization with epidermotropism in monoblastic leukemia].

J. Grob, J. Bonerandi, N. Horchowski, 1988, Annales de dermatologie et de venereologie.

The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: A prospective study

J. Grob, M. Richard, P. Wolkenstein, 2002, International journal of cancer.

Excess of Nevi Related to Immunodeficiency: A Study in HIV-Infected Patients and Renal Transplant Transplant Recipients

L. Vaillant, J. Roujeau, J. Grob, 1996 .

ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

P. Gaulard, R. Bouabdallah, D. Olive, 2020, Blood advances.

[Ulceronecrotic purpura revealing Waldenström's macroglobulinemia].

J. Grob, M. Richard, F. Retornaz, 2001, Presse medicale.

Learning from examples to automatically cluster pigmented skin lesions

Sébastien Paris, Bernard Fertil, Julien Lefèvre, 2013, 2013 IEEE 10th International Symposium on Biomedical Imaging.

The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer.

K. Baumstarck, P. Auquier, O. Chinot, 2012, European journal of cancer.

Early Phase of Primary Melanoma Growth from the Patient Point of View: A Prospective Cross Sectional Study on Melanoma over 1 mm in Thickness

J. Grob, A. Loundou, C. Gaudy-Marqueste, 2020, Acta dermato-venereologica.

Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study.

J. Grob, M. Avril, C. Gaudy-Marqueste, 2009, Archives of dermatology.

Evidence of a limited intra-individual diversity of nevi: intuitive perception of dominant clusters is a crucial step in the analysis of nevi by dermatologists.

J. Malvehy, L. Thomas, B. Fertil, 2013, The Journal of investigative dermatology.

[Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)].

J. Grob, B. Dréno, M. Avril, 2006, Bulletin du cancer.

1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2020 .

[Morel-Lavallee syndrome of the lower leg].

J. Grob, M. Richard, S. Fourcade, 2012, Annales de dermatologie et de vénéréologie.

Congenital and disseminated pyogenic granuloma-like vascular lesions.

N. André, J. Grob, S. Mallet, 2015, Acta dermato-venereologica.

We report an exceptional case of multiple cutaneous and visceral neonatal pyogenic granuloma

N. André, J. Grob, S. Mallet, 2015 .

Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001–2006

L. Naldi, P. Elsner, J. Bouwes Bavinck, 2010, The British journal of dermatology.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

S. Spector, C. Bindslev‐Jensen, J. Grob, 2014, The Journal of investigative dermatology.

9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)

J. Wolchok, B. Neyns, J. Grob, 2009 .

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

I. Bièche, S. Chevret, J. Grob, 2020 .

Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study

J. Lunceford, Chunsheng Zhang, J. Larkin, 2019, Prevention, Early Detection, and Interception.

Macrophage activation syndrome: A new complication of checkpoint inhibitors.

J. Grob, C. Gaudy-Marqueste, B. Guillot, 2017, European journal of cancer.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic / Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines : A Randomized , Placebo-Controlled Study

S. Spector, C. Bindslev‐Jensen, J. Grob, 2010 .

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

D. Schadendorf, J. Malvehy, H. Gogas, 2021, Journal for ImmunoTherapy of Cancer.

Efficacy and Safety of Desloratadine in Adults with Chronic Idiopathic Urticaria

P. Auquier, J. Ortonne, J. Grob, 2007, American journal of clinical dermatology.

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

CO13. Sinonasal mucosal melanomas. About the impact of initial localization and therapeutic modalities on survival: a series of 35 cases

J. Grob, M. Richard, J. Michel, 2011 .

Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes

J. Grob, J. Lachapelle, 2008, Current medical research and opinion.

Dermatomal Pruritus of the Upper Limb: A Manifestation of Nerve Root Compression due to Degenerative Spine Disease?

J. Grob, J. Bonerandi, 1987, The Journal of dermatology.

[Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases].

J. Grob, M. Richard, M. Jreissati, 2001, Annales de dermatologie et de venereologie.

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

D. Schadendorf, P. Ascierto, A. Eggermont, 2022, NEJM Evidence.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, P. Ascierto, C. Blank, 2023, European journal of cancer.

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.

J. Grob, C. Robert, C. Lebbé, 2021, European journal of cancer.

Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity.

J. Grob, J. Bonerandi, 1989, Journal of the American Academy of Dermatology.

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067).

D. Schadendorf, R. Dummer, J. Wolchok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A cooperative effort of the Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology

J. Roujeau, J. Grob, P. Wolkenstein, 2015 .

TREATMENT OF LARGE BASAL-CELL CARCINOMAS WITH INTRALESIONAL INTERFERON-ALPHA-2a

J. Grob, J. Bonerandi, A. Collet, 1988, The Lancet.

Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

J. Schachter, J. Grob, N. Basset-Seguin, 2019, Annals of Oncology.

Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients.

L. Vaillant, J. Roujeau, J. Grob, 1996, Journal of Investigative Dermatology.

[Evaluation of dermatology consultations in a prospective multicenter study involving a French teaching hospital].

P. Berbis, J. Grob, M. Richard, 2009, Annales de dermatologie et de vénéréologie.

Killing efficacy of a new silicon phthalocyanine in human melanoma cells treated with photodynamic therapy by early activation of mitochondrion‐mediated apoptosis

J. Grob, P. Verrando, R. Decréau, 2004, Experimental dermatology.

COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).

K. Flaherty, A. Arance, J. Grob, 2017 .

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019

P. Ascierto, H. Zarour, A. Testori, 2020, Journal of Translational Medicine.

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

D. Schadendorf, P. Ascierto, E. Lipson, 2022, Journal of Clinical Oncology.

D. Schadendorf, E. Lipson, H. Tawbi, 2023, European journal of cancer.

melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

P. Ascierto, R. Dummer, J. Wolchok, 2016 .

Management of cervical lymph node recurrence of melanoma of the head and neck.

J. Grob, O. Mundler, M. Zanaret, 2009, Revue de laryngologie - otologie - rhinologie.

Quality of life in a heterogeneous sample of caregivers of cancer patients: an in-depth interview study.

A. Loundou, P. Auquier, J. Grob, 2011, European journal of cancer care.

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

P. Ascierto, J. Larkin, A. Ribas, 2017, Journal of Translational Medicine.

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

A. Hauschild, D. Schadendorf, K. Flaherty, 2020 .

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.

P. Ascierto, I. Krajsová, J. Grob, 2019, Journal of Clinical Oncology.

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

HVEM: A novel cosignaling molecule of major interest in melanoma.

S. Granjeaud, D. Olive, E. Tartour, 2017 .

[Early detection of melanoma. Discussing a new approach].

J. Grob, Caroline Gaudy, 2007, La Revue du praticien.

Chapter 4. Epidemiology

J. Grob, 2007 .

Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.

J. Grob, M. Richard, C. Gaudy-Marqueste, 2011, Archives of dermatology.

Automatic classification of skin lesions using color mathematical morphology-based texture descriptors

Johan Debayle, Mehdi Rahim, Yanal Wazaefi, 2015, International Conference on Quality Control by Artificial Vision.

[Melanoma and its risk factors. Epidemiology and consequences in detection and prevention].

J. Grob, J. Bonerandi, 1989, Annales de dermatologie et de venereologie.

Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

C. Garbe, E. Espinosa, A. Schueler, 2016 .

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis

J. Grob, C. Cognet, C. Gaudy-Marqueste, 2012, The British journal of dermatology.

Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma

J. Larkin, A. Ribas, C. Blank, 2015 .

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.

A. Lallas, I. Zalaudek, A. Hauschild, 2023, European journal of cancer.

Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'.

I. Zalaudek, A. Hauschild, J. Malvehy, 2020, European journal of cancer.

Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study

R. Dummer, J. Grob, J. Lear, 2023, European Journal of Dermatology.

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

P. Ascierto, R. Dummer, M. Del Vecchio, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Telangiectasia during amlodipine therapy].

J. Grob, S. Mallet, M. Richard, 2013, Annales de dermatologie et de venereologie.

Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA).

C. Garbe, J. Grob, C. Lebbé, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)

P. Ascierto, J. Kirkwood, P. Durani, 2023, SKIN The Journal of Cutaneous Medicine.

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

D. Schadendorf, P. Ascierto, E. Lipson, 2023, NEJM Evidence.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

A. Hauschild, D. Schadendorf, P. Ascierto, 2019, European journal of cancer.

1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.

D. Schadendorf, P. Ascierto, J. Kirkwood, 2023, Journal of Clinical Oncology.

Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).

J. Taube, J. Kirkwood, M. Del Vecchio, 2023, Journal of Clinical Oncology.

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

P. Ascierto, J. Larkin, M. Mandalà, 2020 .

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

J. Taube, R. Dummer, R. Scolyer, 2023, Cancer Research.

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf, P. Ascierto, A. Ribas, 2014 .

BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006

A. Ribas, C. Blank, J. Schachter, 2018 .

Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365

A. Hauschild, C. Blank, W. Miller, 2012 .

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy.

J. Grob, M. Richard, C. Gaudy-Marqueste, 2006 .

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

P. Ascierto, A. Arance, P. Queirolo, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cost-effectiveness of interferon-α2 as adjuvant therapy in malignant melanoma

J. Grob, A. Lafuma, 2003 .

Cost-effectiveness of interferon-alpha2 as adjuvant therapy in malignant melanoma.

J. Grob, A. Lafuma, 2003, Expert opinion on pharmacotherapy.

[Basal-cell and linear unilateral adnexal hamartoma (or linear unilateral basal-cell nevus)].

H. Zarour, J. Grob, J. Bonerandi, 1992, Annales de dermatologie et de vénéréologie.

[Ocular allergies for the dermatologist: conjunctivitis].

J. Grob, M. Castelain, 2002, Annales de dermatologie et de venereologie.

Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.

A. Hauschild, P. Ascierto, J. Grob, 2013 .

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

H. Gogas, J. Grob, L. Demidov, 2021 .

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2008, Clinical Cancer Research.

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

D. Schadendorf, K. Flaherty, A. Ribas, 2016, The Lancet. Oncology.

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

A. Hauschild, C. Blank, W. Miller, 2012, The Lancet.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

J. Larkin, A. Ribas, C. Blank, 2015, The New England journal of medicine.

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.

J. Grob, F. Albarel, I. Morange, 2015, European journal of endocrinology.

Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.

D. Olive, M. Mohty, J. Grob, 2010, Immunobiology.

[Erosive pustulosis of the scalp. A spongiform pustular dermatosis?].

J. Grob, J. Bonerandi, R. Choux, 1993, Annales de dermatologie et de venereologie.

Cognitive training with photographs as a new concept in an education campaign for self‐detection of melanoma: a pilot study in the community

J. Grob, C. Gaudy-Marqueste, G. Bonnelye, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.

I. Zalaudek, J. Becker, J. Malvehy, 2015, European journal of cancer.

Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma.

J. Grob, M. Richard, A. Loundou, 2014, European journal of cancer.

P. Ascierto, R. Dummer, J. Wolchok, 2017, The Lancet. Oncology.

[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].

J. Grob, M. Richard, S. Lagrassa, 2005, Annales de dermatologie et de venereologie.

Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma.

L. Xerri, H. Zarour, J. Grob, 1995, Archives of dermatology.

[Extracorporeal photochemotherapy in therapy-refractory subacute lupus].

J. Grob, M. Richard, P. Poullin, 2002, Annales de dermatologie et de venereologie.

New systemic treatments to improve survival in melanoma patients whose brain metastases are controlled by an on demand Gamma-knife radiosurgical strategy.

J. Régis, J. Grob, M. Richard, 2016 .

Multiple Large Solar Lentigos on the Upper Back as Clinical Markers of Past Severe Sunburn: A Case-Control Study

J. Grob, C. Derancourt, J. Guillaume, 2006, Dermatology.

Melanoma prevention: evaluation of a health education campaign for primary schools.

J. Grob, J. Guillaume, S. Bastuji‐Garin, 1999, Archives of dermatology.